ArticleNew microbes and new infections2018
Genotyping and molecular detection of multidrug-resistant
Article in New microbes and new infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Distribution of Mycobacterium Tuberculosis Lineages and Sublineages by Drug Profile in Ethiopia: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2025Pooled it
- Molecular detection of rifampicin-resistantFrontiers in medicine · 2024Pooled it
- Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Epidemiology of tuberculous lymphadenitis in Africa: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Genetic diversity ofNew microbes and new infections · 2024Article
- Patterns and profiles of drug resistance-conferring mutations inFrontiers in public health · 2024Article
- Spiritual Holy Water Sites in Ethiopia: Unrecognized High-Risk Settings for Transmission of Pulmonary Tuberculosis.International journal of microbiology · 2024Article
- Drug Resistance in Tuberculous Lymphadenitis: Molecular Characterization.Tuberculosis research and treatment · 2023Article
- Phenotypic Drug Resistance Pattern and Mutation Characteristics ofInfection and drug resistance · 2023Article
- Review
- Utility of line probe assay in detecting drug resistance and the associated mutations in patients with extrapulmonary tuberculosis in Addis Ababa, Ethiopia.SAGE open medicine · 2022Article
- Drug Resistance Conferring Mutation and Genetic Diversity ofInfection and drug resistance · 2021Article
- Genotyping and drug susceptibility testing ofNew microbes and new infections · 2020Article
- Epidemiology and the diagnostic challenge of extra-pulmonary tuberculosis in a teaching hospital in Ethiopia.PloS one · 2020Article
- Molecular detection of Mycobacterium tuberculosis sensitivity to rifampicin and isoniazid in South Gondar Zone, northwest Ethiopia.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major public health problem. Drug-resistance surveillance data show that 3.9% of new and 21% of previously treated TB cases were estimated to have had rifampicin/ multidrug-resistant tuberculosis (MDR/RR-TB) in 2015. This implies that the MDR-TB is increasing alarmingly. Hence, a better understanding of drug resistance mechanisms and genotypes associated with multidrug resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.